Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients

Irreversible acute rejection of the transplanted heart usually has a fatal outcome. Predicting which recipients are most likely to reject might allow closer monitoring and modification of treatment protocols to prevent graft loss. Recipients genetically predisposed to produce more TNF-α are those wh...

Full description

Saved in:
Bibliographic Details
Published in:Human immunology 2001-02, Vol.62 (2), p.140-142
Main Authors: Azzawi, M, Hasleton, P.S, Yonan, D.M.TurnerN, Sinnott, A.K.DeiraniyaP.J, Hutchinson, I.V
Format: Article
Language:English
Subjects:
Acute Disease
acute rejection
Adjuvants, Immunologic - therapeutic use
Alleles
Antilymphocyte Serum - therapeutic use
Azathioprine - therapeutic use
Cyclosporine - therapeutic use
gene polymorphism
Genetic Carrier Screening
Genotype
Graft Rejection - genetics
Graft Rejection - immunology
Graft Rejection - mortality
Graft Rejection - pathology
heart transplantation
Heart Transplantation - immunology
Heart Transplantation - mortality
Heart Transplantation - pathology
Humans
Immunosuppressive Agents - therapeutic use
Polymorphism, Genetic - immunology
Prednisolone - therapeutic use
TNF-α
Tumor Necrosis Factor-alpha - biosynthesis
Tumor Necrosis Factor-alpha - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Irreversible acute rejection of the transplanted heart usually has a fatal outcome. Predicting which recipients are most likely to reject might allow closer monitoring and modification of treatment protocols to prevent graft loss. Recipients genetically predisposed to produce more TNF-α are those who suffer the most acute rejection episodes. Here we show that TNF-α genotype is strongly associated with death due to acute cell-mediated heart transplant rejection (Chi-square = 28.57, p < 0.0001). This subgroup of recipients should be given optimally tissue matched transplants and should be treated with the most effective immunosuppressive regimens.
ISSN:0198-8859
1879-1166
DOI:10.1016/S0198-8859(00)00235-4